Technology ID
TAB-757

Oral Treatment of Hemophilia

E-Numbers
E-281-2001-0
Lead IC
NIAID
Co-Inventors
Alpan, Oral
Matzinger, Polly
Kamala, Tirumalai
Velander, William
ICs
NIAID
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Development Stages
Pre-Clinical (in vitro)
Development Status
  • In vitro data available
  • In vivo data available (animal)
This invention portrays a simple method for treatment of antigen-deficiency diseases by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. This method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.
Commercial Applications
  • Oral-based treatment for hemophilia A or B
Competitive Advantages
  • Less invasive than current modes of treatment
  • Reduced inflammatory response
  • Immunotolerization against future bleeding episodes
Licensing Contact:
Rainwater, Charles
[email protected]